Intra-abdominal fibrosis after systemic and intraperitoneal therapy containing fluoropyrimidines

Cancer

Volumn 88, Issue 11, 2000, Pages 2447-2451

  Fata, Farid ^a   Ron, Ilan G ^a   Maluf, Fernando ^a   Klimstra, David ^a   Kemeny, Nancy ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal carcinoma; Fibrotic mass; Intraperitoneal chemotherapy; Intraperitoneal fibrosis

Indexed keywords

CISPLATIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; MELPHALAN;

ADULT; ARTICLE; CASE REPORT; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; FEMALE; FIBROSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PERITONEUM; PRIORITY JOURNAL;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FIBROSIS; FLOXURIDINE; HUMANS; INFUSIONS, PARENTERAL; LEUCOVORIN; MIDDLE AGED; PERITONEUM;

EID: 0034212383     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000601)88:11<2447::AID-CNCR4>3.0.CO;2-4     Document Type: Article

References (34)

1. Muggia FM. Colorectal cancer: speculations on the role of intraperitoneal therapy. Semin Oncol 1985;12:112-5.
2. Markman M. Intraperitoneal chemotherapy. Semin Oncol 1991;18:248-54.
3. Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, et al. Intraperitoneal cisplatin and etoposide in the treatment of refractory and recurrent ovarian carcinoma. J Clin Oncol 1989;7:1327-32.
4. Sautner T, Hofbauer F, Depisch D. Adjuvant intraperitoneal cisplatin chemotherapy does not improve long-term survival after surgery for advanced gastric cancer. J Clin Oncol 1994; 12:970-4.
5. Sugarbaker PH, Gianola FJ, Speyer JL, Klecker R. Prospective randomized trial of intravenous vs. intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Semin Oncol 1985;12:101-11.
6. Alberts D, Liu P, Hannigan E, O'Toole R, Williams S, Young J, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950-5.
7. Howell SB, Pfeifle CE, Olshen RA. Intraperitoneal chemotherapy with melphalan. Ann Intern Med 1984;101:14-8.
8. Ozols RF, Young RC, Speyer JL, Myers E. Phase I and pharmacological studies of adriamycin administered intraperitoneally to patients with ovarian cancer. Cancer Res 1982; 42:4265-9.
9. Howell SB, Pfeifle CE, Wung WE, Olshen RA, Lucas WE, Yon JL. Intraperitoneal cisplatin with sodium thiosulfate protection. Ann Intern Med 1982; 97:845-51.
10. Speyer JL, Collins JM, Dedrick RL, Brennan MF, Buckpitt AR, Londer H. Phase I pharmacological studies of 5-fluorouracil administered intraperitoneally, Cancer Res 1980;40:567-72.
11. Howell SB, Chu BB, Wung WE, Markman M. Long duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions. J Clin Oncol 1984;2:662-9.
12. King ME, Pfeifle CE, Howell SB. Intraperitoneal cytosine arabinoside in ovarian carcinoma. J Clin Oncol 1984;2:662-9.
13. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis L. Phase I of intraperitoneal paclitaxel: a Gynecologic Oncology Group study. J Clin Oncol 1992;10:1485-91.
14. Edwards R, Gooding W, Lembersky B, Colonello K, Hammond R, Paradise C, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15:3399-407.
15. Speyer JL. The rationale behind intraperitoneal chemotherapy in gastrointestinal malignancies. Semin Oncol 1985;12: 23.
16. Collins JM, Dedrick RL, King FG, Speyer JL, Myers CE. Nonlinear pharmacokinetic models for 5-fluorouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 1980;28:235-46.
17. Ensminger MD, Rosowsky A, Raso V, Levin DC, Glode M, Come S, et al. A clinical pharmacological evaluation of hepatic arterial infusion of 5-fluoro-2′deoxyuridine and 5-fluorouracil. Cancer Res 1978;38:3784-92.
18. Mini E, Moroson BA, Bertino JR, Blessing A. Cytotoxicity of fluxoridine and 5-fluorouracil in human leukemic cells: enhancement by leucovorin. Cancer Treat Rep 1978;71:381-9.
19. Matsuoka H, Furusawa M, Tomoda H, Seo Y, Sugimachi K. Increased cytotoxicity of 5′-deoxy-5-fluorouridine by prolonged culture with folinic acid. Anticancer Res 1993;13: 2201-6.
20. Crookes P, Leichman CG, Leichman L, Tan M, Laine L, Stain S, et al. Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. Cancer 1997;79:1767-75.
21. Kelsen DP, Saltz L, Cohen AM, Yao TJ, Enker W, Tong W, et al. A phase I trial of immediate postoperative intraperitoneal floxuridine and leucovorin plus systemic 5-fluorouracil and levamisole after resection of high risk colon cancer. Cancer 1994;74:2224-33.
22. Speyer JL, Sugarbaker PH, Collins JM, Dedrick RL, Klecker RW Jr., Myers CE. Portal levels land hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res 1981;41:1916-22.
23. Muggia FM, Chan KK, Russel C, Colombo N, Speyer JL, Segal K, et al: Phase I and pharmacological evaluation of intraperitoneal 5-fluoro-2′deoxyuridine. Cancer Chemother Pharmacol 1991;28:241-50.
24. Weidner N, Smith JG, LaVanway JM. Peptic ulceration with marked epithelial atypia following hepatic arterial infusion chemotherapy. Am J Surg Pathol 1983;7:261-8.
25. Haq MM, Valdes LG, Peterson DF, Gourley WK. Fibrosis of extrahepatic biliary system after continuous hepatic artery infusion of floxuridine through an implantable pump (Infusaid pump). Cancer 1986;57:1281-3.
26. Brown KT, Kemeny N, Berger MF, Getrajdman GI, Napp T, Fong Y, et al. Obstructive jaundice in patients receiving hepatic artery infusional chemotherapy: etiology, treatment, implications, and complications after transhepatic biliary drainage. J Vasc Intern Radiol 1997;8:229-34.
27. Doria M, Shepared K, Levin B, Riddell RH. Liver pathology following hepatic arterial infusion chemotherapy: hepatic toxicity with FUDR. Cancer 1986;58:855-61.
28. Pettavel J, Gardiol D, Bergier N, Schnyder P. Necrosis of main bile ducts caused by hepatic artery infusion of 5-fluoro-2-deoxyuridine. Reg Cancer Treat 1988;1:83-92.
29. Ludwig J, Kin CH, Wiener RH, Kron RF. Floxuridine-induced sclerosing cholangitis: an ischemic cholagiopathy? Hepatology 1989;9:215-8.
30. Vlasveld LT, Taal BG, Kroon BB, Gallee MP, Rodenhius S. Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. Cancer Chemother Pharmacol 1992;29:405-8.
31. Atiq OT, Kelsen DP, Shiu MH, Saltz L, Tong W, Niedzwiecki D, et al. Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. J Clin Oncol 1993;11:425-33.
32. Adab FA, Mould JJ. Carboplatin and retroperitoneal fibrosis. Clin Oncol 1992;14:327-8.
33. Ubhi SS, McCulloch P, Veitch PS. Preliminary results of the use of intraperitoneal carbon-adsorbed mitomycin C in intra-abdominal malignancy. Br J Cancer 1997;76:1667-9.
34. Hastie K, Ramesar K, Cuschieri A. Local and systemic effects of repeated intraperitoneal epirubicin treatment. Eur J Surg Oncol 1991;17:379-83.